Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: selective estrogen receptor modulators - Signal

Drug Profile

Research programme: selective estrogen receptor modulators - Signal

Alternative Names: CC-25493; Research programme: interleukin-6 antagonists - Signal; SP 1496; SP 263; SP 290; SP 291; SP 500263

Latest Information Update: 05 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Signal Research Division
  • Class Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Postmenopausal osteoporosis; Urinary incontinence

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top